Prolia® is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily ...
The FDA approved Stoboclo and Osenvelt as interchangeable biosimilars for Prolia and XGEVA, enhancing patient access and reducing costs. These biosimilars treat osteoporosis and bone mass loss in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results